[Admin]

A place to discuss stalled progress and plateaus in the context of semaglutide research and experience — lifestyle variables, adherence, and expectations, not prescriptive dosage advice.

Topics for this thread

• Lifestyle variables that may relate to a plateau — nutrition, activity, sleep
• Adherence to study or treatment protocols
• Expectations vs. observed trajectory
• General observations from published research on weight-loss trajectory over time

If you find published research specifically addressing plateaus or long-term trajectory with semaglutide, the Clinical Studies and Research Updates thread is the right place to share it.

This is a discussion of patterns and general variables — not a place for specific dosage-adjustment recommendations.

[PepGorilla]

A few different patterns can look like “a plateau” and they’re worth separating, since they don’t all mean the same thing.

The trial data itself has a plateau shape. In the STEP 1 trial (Wilding et al., NEJM 2021), the weight-loss curve for semaglutide 2.4mg wasn’t linear the whole way through — it climbed steadily and then flattened out around week 60-68, even for participants who stayed on treatment through week 68. That flattening happened while people were still on a stable maintenance dose, so a slowing trajectory around that timeframe is consistent with what was observed in the actual research, not necessarily a sign that something has stopped working.

Metabolic adaptation is the more likely mechanism than “tolerance.” As body mass drops, resting energy expenditure drops with it — a lighter body burns fewer calories at rest. That means the same intake/activity level produces a shrinking deficit over time purely from that adaptation, independent of anything happening at the receptor level. This is a well-documented phenomenon across basically every sustained weight-loss intervention, not specific to GLP-1 agonists.

End-of-interval effects. With once-weekly dosing, some people notice appetite suppression feels most pronounced in the days right after dosing and less pronounced toward the end of the week — plasma levels aren’t perfectly flat across a 7-day interval. That can read as “it’s wearing off” when it’s more about where you are in the dosing cycle.

Scale plateau vs. composition plateau. Body composition (fat mass vs. lean mass vs. water) can keep shifting even when total scale weight holds steady for a few weeks — this is a common confound in any weight-loss trajectory, not unique to this compound.

None of this is a recommendation to adjust anything — just the variables that show up in the published research when people describe a stall. Curious whether others here have seen their own trajectory match the ~60-68 week flattening pattern from the trials, or whether it showed up earlier/later.

[Author]

Posts